Connect Biopharma Holdings

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.

SAN DIEGO and TAICANG, China, July 05, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will be hosting one-on-one investor meetings at the SVB Securities Therapeutics Forum, taking place on July 11-12, 2023 in New York, NY.

Connect Biopharma to Participate in the SVB Securities Therapeutics Forum

SAN DIEGO, CA and TAICANG, China, June 01, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced positive data at Week 48 from Phase 2 trial (CN002) for icanbelimod (formerly known as CBP-307), a once-daily, orally administered, selective sphingosine 1-phosphate receptor 1 (S1P1) modulator in development for the treatment of ulcerative colitis (UC).

Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis

CDE's Pre-NDA Feedback Confirms CBP-201 for Atopic Dermatitis on Track  for NDA Submission in China by End of First Quarter 2024

Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update

The stock price of Connect Biopharma Holdings Ltd (NASDAQ: CNTB) surged by over 20% intraday today. This is why.

CNTB Stock Surges Over 20%: Explanation

SAN DIEGO & TAICANG, China & SUZHOU, China--(BUSINESS WIRE)--Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD) showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16.

Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

Connect Biopharma Holdings Ltd. CNTB, -3.51% stock rose more than 40% in the extended session Friday after the company said that analysis of a trial involving one of its therapies to treat moderate-to-severe atopic dermatitis showed “rapid and sustained improvement” in signs and symptoms of the illness as compared to a placebo.

Connect Biopharma stock up more than 40% after trial data

SAN DIEGO & TAICANG, China & SUZHOU, China--(BUSINESS WIRE)--Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, announced that post hoc data analysis from the Phase 2b CBP-201 global trial in moderate-to-severe atopic dermatitis (AD) showed that CBP-201 led to rapid and sustained improvement in AD signs and symptoms across all four body regions,

Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions

SAN DIEGO & TAICANG & SUZHOU, China--(BUSINESS WIRE)--Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that two abstracts from its CBP-201 clinical development program in atopic dermatitis (AD) have been accepted for presentation at the American Academy of Dermatology (AAD), March 17-21, 2023, in New Orleans, LA.

Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting

SAN DIEGO and TAICANG, SUZHOU, China, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced it will be presenting, and hosting one-on-one meetings, at the following conferences in February and March 2023:

Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California

Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of CBP-201 in atopic dermatitis (AD); Longer cash runway permits continued evaluation of potential partnership opportunities to advance the global AD Phase 3 program

Connect Biopharma Provides Business and Clinical Development Program Update

SAN DIEGO and TAICANG, SUZHOU, China, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that Zheng Wei, PhD, Co-Founder and CEO of Connect Biopharma will present a corporate update on January 9, at 9:00 am PST, during the upcoming Biotech Showcase taking place in person January 9 – 11, 2023.

Connect Biopharma to Present at the San Francisco Biotech Showcase in January

SAN DIEGO and TAICANG, SUZHOU, China, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced it will be presenting and/or hosting one-on-one meetings at the following upcoming investor and scientific conferences:

Connect Biopharma To Present at Upcoming Investor and Scientific Conferences

SAN DIEGO and TAICANG, China, Oct. 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Connect Biopharma Holdings Limited (Nasdaq: CNTB), please note that in the "About the Trial" section, the fourth sentence should read "Stage 2 36-week maintenance period", not "Stage 2 16-week maintenance period" as previously stated. The corrected release follows:

CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

SAN DIEGO and TAICANG, China, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced topline results for the primary analysis population of the pivotal trial of the Company's lead candidate, CBP-201, in patients with moderate-to-severe atopic dermatitis (AD) in China. This multi-center, randomized, double-blind, parallel group, placebo-controlled trial is evaluating the efficacy and safety of CBP-201 as well as the potential for an extended CBP-201 dosing interval during the maintenance phase of treatment.

Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT, tomorrow, Tuesday, October 4

Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis

The stock is down 80% year-to-date due to disappointing study results from the company's two lead product candidates, CBP-201 and CBP-307. CBP-307 development has been put on ice.

Connect Biopharma Is A Sleeper Heading Into October Data Readout

Connect Biopharma Holdings Limited (NASDAQ:CNTB ) Q2 2022 Results Conference Call September 13, 2022 4:30 PM ET Company Participants Ina McGuinness - IR Dr. Zheng Wei - Co-Founder and CEO Dr. Chin Lee - Chief Medical Officer Steven Chan - CFO Conference Call Participants Louise Chen - Cantor Fitzgerald Thomas Smith - SVB Securities Kelly Shi - Jefferies Joe Catanzaro - Piper Sandler Operator Good day and thank you for standing by. Welcome to Connect Biopharma First Half 2022 Financial Results Conference Call.

Connect Biopharma Holdings Limited (CNTB) Q2 2022 Earnings Call Transcript

– Company expects to report top-line data from China pivotal trial for lead drug candidate CBP-201 in atopic dermatitis in October 2022 –

Connect Biopharma Reports First Half 2022 Financial Results and Provides Business Update

Conference call and webcast to follow at 1:30 p.m. PDT/4:30 p.m. EDT

Connect Biopharma to Report First Half 2022 Financial Results on September 13

– CBP-174 in development for pruritus associated with allergic and inflammatory skin diseases, including atopic dermatitis, was observed to be safe and well-tolerated –

Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study

— Connect to Evaluate Efficacy and Safety Data on 255 Patients Already Enrolled —

Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022

AcelRx Pharmaceuticals

Geron

Can these penny stocks climb this week? The post Hot Penny Stocks That Are Climbing Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks That Are Climbing Right Now

Connect Biopharma Holdings Limited Sponsored ADR (CNTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Rating Upgrade to Buy

SAN DIEGO, CA and TAICANG, SUZHOU, China, June 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Dr. Zheng Wei, Co-Founder & Chief Executive Officer, and Steven Chan, Chief Financial Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 am ET.

Connect Biopharma to Participate at the Jefferies Healthcare Conference

SAN DIEGO, CA and TAICANG, China, May 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research will be presenting data describing the immunological profile of CBP-201 based on preclinical experiments, demonstrating reductions in clinically validated biomarkers of Th2-driven inflammation. Additionally, the Company will be reporting distinct binding epitopes, higher binding affinity, and increased potency demonstrating improved target engagement properties with CBP-201 compared to dupilumab. The data will be presented in a poster at the Society for Investigative Dermatology Annual Conference, May 18-21 at the Oregon Convention Center, Portland, Oregon.

News for Connect Biopharma Holdings Stock (CNTB)